A randomized controlled trial found that patients who were given a 12-month injection of antipsychotic Risperdal were more likely to adhere to treatment, causing researchers to recommend the injection before the current oral pill method of ingestion. Patients who currently take Risperdal may be at a risk of side effects, including breast tissue growth in young boys.
Risperdal has been associated with gynecomastia, a condition in which males develop unwanted breast tissue in young boys. The drug’s manufacturer Janssen Pharmaceuticals and parent company Johnson & Johnson have faced multiple Risperdal lawsuits alleging that the drug caused breast tissue growth in young boys and male adolescents.
In February, J & J paid more than $1 million to a 22-year old Alabama man who developed size 46DD breasts after being given Risperdal since age 12. J & J has also settled several lawsuits brought on by states that alleged the company violated consumer protection laws and illegally marketed Risperdal for unapproved uses.